AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23233719 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole + Temsirolimus (in patients ≤ 65 years)
Number of subjects: 1112
Study 23233719 — intervention group
Group type: COMPARATOR
Intervention: Letrozole + Placebo (in patients ≤ 65 years)
Number of subjects: 1112
Study 21891901 — intervention group
Group type: EXPERIMENTAL
Intervention: Sign Grading System
Number of subjects: 50
Study 19573188 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential learning
Number of subjects: 210
Study 19573188 — intervention group
Group type: COMPARATOR
Intervention: Guided learning
Number of subjects: 210
Study 17452167 — intervention group
Group type: EXPERIMENTAL
Intervention: VLTS-589 (Del-1)
Number of subjects: 105
Study 17452167 — intervention group
Group type: COMPARATOR
Intervention: Poloxamer 188 (control)
Number of subjects: 105
Study 15188088 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-stroke massage (M)
Number of subjects: 32
Study 15188088 — intervention group
Group type: COMPARATOR
Intervention: Control groups (C) - relaxation and perception
Number of subjects: 32
Study 11570683 — intervention group
Group type: EXPERIMENTAL
Intervention: Liner Bond 2 (self‐etching) (LB2)
Number of subjects: 60
Study 11570683 — intervention group
Group type: EXPERIMENTAL
Intervention: Liner Bond 2V (self‐etching) (LB2V)
Number of subjects: 60
Study 11570683 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid Bond (total etching) (SB)
Number of subjects: 60
Study 11570683 — intervention group
Group type: EXPERIMENTAL
Intervention: Opti Bond Solo (single component) (OBS)
Number of subjects: 60
Study 11570683 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Bond LC (filled) (FBLC)
Number of subjects: 60
Study 11570683 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond 2‐1 (single component) (P&B2‐1)
Number of subjects: 60
Study 9663726 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg o.d. + Amoxycillin 500 mg q.d.s. after meals for 2 weeks (group LA)
Number of subjects: 101
Study 9663726 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg o.d. + Amoxycillin 500 mg q.d.s. + Ecabet sodium 1000 mg b.d. after meals for 2 weeks (group LAE)
Number of subjects: 101
Study 9663726 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole + Amoxycillin (group LA)
Number of subjects: 101
Study 9663726 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole + Amoxycillin + Ecabet sodium (group LAE)
Number of subjects: 101
Study 7830161 — intervention group
Group type: EXPERIMENTAL
Intervention: Microprocessor-controlled cradle providing motion and sound stimulation
Number of subjects: 38
Study 7830161 — intervention group
Group type: EXPERIMENTAL
Intervention: Microprocessor-controlled cradle
Number of subjects: 38
Study 7830161 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 38
Study 2932137 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms of nebulized ipratropium bromide after 10 mg salbutamol by nebulizer
Number of subjects: 24
Study 2932137 — intervention group
Group type: COMPARATOR
Intervention: 10 mg salbutamol (two doses 2 hours apart)
Number of subjects: 24
Study 30891604 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of EV71 vaccine (dose 1) and HepB on day 1 and EV71 vaccine (dose 2) and MenA on day 30 (SI group)
Number of subjects: 775
Study 30891604 — intervention group
Group type: COMPARATOR
Intervention: Administration of doses 1 and 2 of EV71 vaccine on days 1 and 30, respectively (SE1 group)
Number of subjects: 775
Study 30891604 — intervention group
Group type: COMPARATOR
Intervention: Administration of HepB and MenA on days 1 and 30, respectively (SE2 group)
Number of subjects: 775
Study 30891604 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 775
Study 30421998 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation strategies (MCII) with Fitbit goal of 10,000 steps per day
Number of subjects: 85
Study 30421998 — intervention group
Group type: COMPARATOR
Intervention: Control group (no self-regulation strategies) with Fitbit goal of 10,000 steps per day
Number of subjects: 85
Study 30421998 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation strategies (MCII)
Number of subjects: 85
Study 26891753 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human G-CSF
Number of subjects: 120
Study 26891753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 25314773 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cycles of cytarabine (average dose) in Group 2
Number of subjects: 243
Study 25314773 — intervention group
Group type: COMPARATOR
Intervention: Standard doses (100 mg/m2) in combination with idarubicin (8‐12 mg/m2) and mitoxantrone (10 mg/m2) in Group 1
Number of subjects: 243
Study 25314773 — intervention group
Group type: EXPERIMENTAL
Intervention: Allo-BMT during first CR
Number of subjects: 243
Study 25314773 — intervention group
Group type: EXPERIMENTAL
Intervention: Unachieved CR after the first cycle
Number of subjects: 243
Study 22377484 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict glucose control based on insulin (I-group; n=21)
Number of subjects: 39
Study 22377484 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict glucose control based on oral agents (O-group; n=18)
Number of subjects: 39
Study 22377484 — intervention group
Group type: COMPARATOR
Intervention: Overall group (n=39)
Number of subjects: 39
Study 20200384 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin < 5.0%
Number of subjects: 11092
Study 20200384 — intervention group
Group type: COMPARATOR
Intervention: Glycated hemoglobin 5.0 to < 5.5%
Number of subjects: 11092
Study 20200384 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin 5.5 to < 6.0%
Number of subjects: 11092
Study 20200384 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin 6.0 to < 6.5%
Number of subjects: 11092
Study 20200384 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin ≥ 6.5%
Number of subjects: 11092
Study 17209215 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin-multimineral supplement with vitamin C, vitamin E, beta-carotene, and zinc (with cupric oxide)
Number of subjects: 0
Study 17209215 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle with a diet rich in antioxidants (lutein, zeaxanthin) and n-3 fatty acids
Number of subjects: 0
Study 17209215 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional nutrients as dietary supplements
Number of subjects: 0
Study 17541671 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hour interactive BAI training workshop
Number of subjects: 26
Study 17541671 — intervention group
Group type: COMPARATOR
Intervention: Lipid management workshop
Number of subjects: 26
Study 14997933 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with amyloid-beta peptide
Number of subjects: 2
Study 11134690 — intervention group
Group type: EXPERIMENTAL
Intervention: 400-mg caplets of Garcinia cambogia (total dose of 2.4 g/day, 1.2 g/day HCA)
Number of subjects: 89
Study 11134690 — intervention group
Group type: COMPARATOR
Intervention: Matched placebos
Number of subjects: 89
Study 8636173 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-bearing in a below-knee walking plaster
Number of subjects: 81
Study 8636173 — intervention group
Group type: COMPARATOR
Intervention: Non-weight-bearing with crutches
Number of subjects: 81
Study 1460157 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 84
Study 1460157 — intervention group
Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 84
Study 3912959 — intervention group
Group type: EXPERIMENTAL
Intervention: Coeliac plexus block
Number of subjects: 17
Study 3912959 — intervention group
Group type: COMPARATOR
Intervention: Pancreaticogastrostomy
Number of subjects: 17
Study 30630862 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine maintenance (50 mg/m2, subcutaneously, days 1‐5, every 4 weeks) until relapse, for a maximum of 12 cycles (N = 56)
Number of subjects: 116
Study 30630862 — intervention group
Group type: COMPARATOR
Intervention: Observation (N = 60)
Number of subjects: 116
Study 30630862 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine maintenance
Number of subjects: 116
Study 30630862 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 116
Study 28829514 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin retained enema, conducted twice every day for at least 30 minutes each time, with treatment courses lasting 7 days.
Number of subjects: 79
Study 28829514 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment plan (Control group).
Number of subjects: 79
Study 28829514 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin retained enema (Observation group).
Number of subjects: 79
Study 26173772 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 50,000 IU/month
Number of subjects: 245
Study 26173772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 23607709 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld MPD tester
Number of subjects: 37
Study 23607709 — intervention group
Group type: COMPARATOR
Intervention: PUVA panel MPD
Number of subjects: 37
Study 21302138 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 5 mg/day
Number of subjects: 22
Study 21302138 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg/day
Number of subjects: 22
Study 19703730 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketamine (10% cream) applied to the symptomatic limb
Number of subjects: 20
Study 19703730 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study 17983368 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate tablets
Number of subjects: 411
Study 17983368 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol plus bisacodyl tablets
Number of subjects: 411
Study 14695958 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention counseling intervention
Number of subjects: 32
Study 14695958 — intervention group
Group type: COMPARATOR
Intervention: Control group (clients who completed the intervention)
Number of subjects: 32
Study 11725734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol alone (25 micrograms every 3 hours for no more than 12 hours)
Number of subjects: 81
Study 11725734 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (transcervical Foley balloon + intravaginal misoprostol)
Number of subjects: 81
Study 9222185 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 0
Study 9222185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8431749 — intervention group
Group type: EXPERIMENTAL
Intervention: Zenoderm (ZM)
Number of subjects: 64
Study 8431749 — intervention group
Group type: COMPARATOR
Intervention: DuoDERM E (DE)
Number of subjects: 64
Study 3126515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.695 g/kg of body weight over a 15‐min period)
Number of subjects: 6
Study 3126515 — intervention group
Group type: COMPARATOR
Intervention: Ethanol placebo
Number of subjects: 6
Study 3126515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 6
Study 31586424 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin (2 mg/kg once daily)
Number of subjects: 49
Study 31586424 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B deoxycholate (1 mg/kg)
Number of subjects: 49
Study 31586424 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 49
Study 31586424 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B deoxycholate
Number of subjects: 49
Study 29367614 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 105
Study 29367614 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 105
Study 29367614 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan
Number of subjects: 105
Study 26892411 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable scaffold (B1)
Number of subjects: 101
Study 26892411 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable scaffold (B2)
Number of subjects: 101
Study 24916063 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 17
Study 24916063 — intervention group
Group type: COMPARATOR
Intervention: Videolaryngoscopy
Number of subjects: 17
Study 22946775 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA ProSeal(TM)
Number of subjects: 51
Study 22946775 — intervention group
Group type: COMPARATOR
Intervention: i-Gel(TM)
Number of subjects: 51
Study 21191437 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based LFQ administration
Number of subjects: 149
Study 21191437 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive voice response system (IVRS)-based LFQ administration
Number of subjects: 149
Study 21191437 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewer-based LFQ administration
Number of subjects: 149
Study 21191437 — intervention group
Group type: COMPARATOR
Intervention: Paper-based LFQ administration
Number of subjects: 149
Study 18655988 — intervention group
Group type: EXPERIMENTAL
Intervention: Neocrom Cohesive (sodium hyaluronate 1.4%)
Number of subjects: 29
Study 18655988 — intervention group
Group type: COMPARATOR
Intervention: Healon (sodium hyaluronate 1.0%)
Number of subjects: 29
Study 16319330 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation (NIMV), applied 3 h/day, 5 days a week, for 3 weeks
Number of subjects: 42
Study 16319330 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation (NIMV)
Number of subjects: 42
Study 16319330 — intervention group
Group type: COMPARATOR
Intervention: Sham-NIMV
Number of subjects: 42
Study 11986591 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep hypothermic circulatory arrest (DHCA)
Number of subjects: 23
Study 11986591 — intervention group
Group type: COMPARATOR
Intervention: Low-flow cardiopulmonary bypass (LF)
Number of subjects: 23
Study 9593937 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG recordings during the decision-making task
Number of subjects: 15
Study 9593937 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental counting of clock sounds
Number of subjects: 15
Study 7618770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac (60 mg)
Number of subjects: 82
Study 7618770 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen (800 mg)
Number of subjects: 82
Study 2677101 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (43 mmol/day)
Number of subjects: 7
Study 2677101 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (175 mmol/day)
Number of subjects: 7
Study 33053 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60, 120 and 240 mg
Number of subjects: 20
Study 33053 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 100 mg
Number of subjects: 20
Study 33053 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg
Number of subjects: 20
Study 33053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30811290 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI arm
Number of subjects: 360
Study 30811290 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 360
Study 27006391 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers Questionnaire 13 items (BQ-13)
Number of subjects: 0
Study 27006391 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity measures
Number of subjects: 0
Study 27006391 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic characteristics
Number of subjects: 0
Study 26303801 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir (5 to 50 mg for genotype 1; 10 to 100 mg for genotype 3) once daily for 5 days
Number of subjects: 48
Study 26303801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23605507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 32.5 mg
Number of subjects: 6
Study 23605507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 21976155 — intervention group
Group type: EXPERIMENTAL
Intervention: Betel nut chewing
Number of subjects: 0
Study 21976155 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 0
Study 21976155 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (disguised chewing)
Number of subjects: 0
Study 21976155 — intervention group
Group type: COMPARATOR
Intervention: Pure control (no chewing)
Number of subjects: 0
Study 21976155 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing (general)
Number of subjects: 0
Study 19364637 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Musculoskeletal Function Assessment Dysfunction Index (SMFA DI)
Number of subjects: 1319
Study 19364637 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Form‐36 Physical Component Summary (SF‐36 PCS)
Number of subjects: 1319
Study 16904441 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation (HoLEP)
Number of subjects: 63
Study 16904441 — intervention group
Group type: COMPARATOR
Intervention: Open transvesical prostatectomy (OP)
Number of subjects: 63
Study 14742331 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal ketamine group (bupivacaine + S(+)-ketamine 0.5 mg x kg(‐1))
Number of subjects: 60
Study 14742331 — intervention group
Group type: COMPARATOR
Intervention: i.v. ketamine group (bupivacaine + S(+)-ketamine 0.5 mg x kg(‐1) i.v.)
Number of subjects: 60
Study 14742331 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine group (plain bupivacaine 0.25% 1 ml x kg(‐1))
Number of subjects: 60
Study 14742331 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal ketamine group
Number of subjects: 60
Study 11569153 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization
Number of subjects: 107
Study 11569153 — intervention group
Group type: COMPARATOR
Intervention: Immobilization (soft collar)
Number of subjects: 107
Study 9189303 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (CR)
Number of subjects: 26
Study 9189303 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 26
Study 1347291 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 41
Study 1347291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 3884688 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mcg of albuterol powder
Number of subjects: 20
Study 3884688 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mcg of albuterol powder
Number of subjects: 20
Study 3884688 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mcg of albuterol powder
Number of subjects: 20
Study 3884688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29128326 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Number of subjects: 80
Study 29128326 — intervention group
Group type: COMPARATOR
Intervention: Healthy Behaviors Training (HBT)
Number of subjects: 80
Study 28286262 — intervention group
Group type: EXPERIMENTAL
Intervention: IV magnesium sulfate (100 mg/kg)
Number of subjects: 162
Study 28286262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 26882812 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 85
Study 26882812 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 85
Study 26882812 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 85
Study 23327664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (model to improve implementation of guidelines)
Number of subjects: 32
Study 23327664 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 32
Study 22023281 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to hostile e‐confederates in chat-room condition
Number of subjects: 134
Study 22023281 — intervention group
Group type: COMPARATOR
Intervention: Exposure to benign e‐confederates in chat-room condition
Number of subjects: 134
Study 22023281 — intervention group
Group type: EXPERIMENTAL
Intervention: Social anxiety
Number of subjects: 134
Study 22023281 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive adolescents
Number of subjects: 134
Study 18334615 — intervention group
Group type: EXPERIMENTAL
Intervention: Hood CPAP
Number of subjects: 0
Study 18334615 — intervention group
Group type: COMPARATOR
Intervention: Conventional nasal system
Number of subjects: 0
Study 16547997 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Harmonic Imaging (THI)
Number of subjects: 23
Study 16547997 — intervention group
Group type: COMPARATOR
Intervention: Conventional Sonography
Number of subjects: 23
Study 14514229 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonporous polytetrafluoroethylene (NP) membrane
Number of subjects: 24
Study 14514229 — intervention group
Group type: COMPARATOR
Intervention: Porous expanded polytetrafluoroethylene (P) membrane
Number of subjects: 24
Study 11117082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound markers (non-cardiovascular and cardiovascular)
Number of subjects: 2080
Study 11117082 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cardiovascular markers
Number of subjects: 2080
Study 11117082 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of right‐to‐left chamber disproportion with CNS, NSF, HB and PY
Number of subjects: 2080
Study 8645387 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (1 mg/kg/day in three divided doses)
Number of subjects: 19
Study 8645387 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 19
Study 1464342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinone (coenzyme Q10) 3 x 33.3 mg/day orally for 4 months
Number of subjects: 25
Study 1464342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 2982622 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/m2 of cyclophosphamide pretreatment before chemotherapy
Number of subjects: 45
Study 2982622 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (cyclophosphamide, vincristine, and methotrexate) without pretreatment
Number of subjects: 45